Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
$0.63
-1.7%
$0.68
$0.49
$2.75
$57.68M1.88273,072 shs112,075 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$3.36
-0.6%
$2.85
$1.10
$6.01
$58.44M1.59420,884 shs162,157 shs
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
$0.02
+5.0%
$0.03
$0.01
$0.03
$12.50M0.3426,885 shs87,112 shs
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$5.38
+8.2%
$6.17
$2.02
$11.00
$62.83M1.89273,171 shs925,965 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-0.60%+2.47%-3.18%-4.03%-65.05%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
+0.30%+7.99%+3.36%+89.89%+45.69%
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
-16.73%-12.05%-31.56%-0.45%+53.15%
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
+5.97%+1.43%-34.12%-2.93%+5.74%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
2.8226 of 5 stars
3.64.00.00.00.01.71.3
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2.0655 of 5 stars
3.61.00.00.02.50.80.6
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.112 of 5 stars
3.73.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
3.17
Buy$5.50770.25% Upside
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
3.20
Buy$28.50748.21% Upside
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
0.00
N/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
3.33
Buy$60.001,015.24% Upside

Current Analyst Ratings Breakdown

Latest PRVCF, UNCY, NRXP, and CNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.00
6/20/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/6/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
5/27/2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$90.00
5/16/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
5/8/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/30/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
4/29/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/29/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/29/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$45.00 ➝ $46.00
4/21/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/AN/AN/AN/A$1.27 per shareN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/A($1.48) per shareN/A
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/AN/AN/AN/A($0.01) per shareN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
$680K100.00N/AN/A$0.72 per share7.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$26.73M-$0.310.00N/AN/AN/A-29.78%-29.08%8/6/2025 (Estimated)
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$25.13M-$2.010.00N/AN/AN/AN/A-355.00%8/13/2025 (Estimated)
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
-$940KN/A0.00N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$36.73M-$5.100.00N/AN/AN/A-277.30%-61.53%N/A

Latest PRVCF, UNCY, NRXP, and CNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q1 2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$0.06N/AN/AN/AN/AN/A
5/15/2025Q1 2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 million
5/14/2025Q1 2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$0.05-$0.05N/A-$0.05N/AN/A
5/14/2025Q1 2025
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
-$1.40-$0.50+$0.90-$0.05N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/AN/A
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/AN/AN/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/A
48.81
48.81
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/A
0.22
0.22
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/AN/AN/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
N/A
1.64
1.64

Institutional Ownership

CompanyInstitutional Ownership
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
14.03%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.27%
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/A
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
40.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
789.70 million87.19 millionNot Optionable
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
217.29 million14.00 millionOptionable
PreveCeutical Medical Inc. stock logo
PRVCF
PreveCeutical Medical
N/A570.65 millionN/ANot Optionable
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
912.64 million11.29 millionNot Optionable

Recent News About These Companies

Unicycive hit with CRL on oxylanthanum carbonate NDA
Unicycive Therapeutics, Inc. (UNCY) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Context Therapeutics stock logo

Context Therapeutics NASDAQ:CNTX

$0.63 -0.01 (-1.71%)
Closing price 04:00 PM Eastern
Extended Trading
$0.66 +0.02 (+3.64%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

NRx Pharmaceuticals stock logo

NRx Pharmaceuticals NASDAQ:NRXP

$3.36 -0.02 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$3.30 -0.05 (-1.64%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

PreveCeutical Medical stock logo

PreveCeutical Medical OTCMKTS:PRVCF

$0.02 +0.00 (+5.02%)
As of 03:47 PM Eastern

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada.

Unicycive Therapeutics stock logo

Unicycive Therapeutics NASDAQ:UNCY

$5.38 +0.41 (+8.25%)
Closing price 04:00 PM Eastern
Extended Trading
$5.53 +0.15 (+2.79%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.